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Over the past 2 decades, numerous studies have provided substan-
tial evidence for an association of alcohol consumption and risk of
breast cancer (Longnecker, 1994). Research has recently focussed
on the role of steroid hormone receptors in the association of
alcohol with breast cancer, given evidence suggesting that alcohol
consumption increases endogenous oestrogen levels (Singletary,
1996) and given the role of oestrogen receptors (ERs) in facilitating
the breast cell-stimulating activity of oestrogen (Stanford et al,
1986; Habel and Stanford, 1993). Results from a large breast cancer
case-control study suggested that the increased risk of breast
cancer associated with alcohol consumption may be restricted to
ER- positive tumours (Nasca et al, 1994), a finding that was not
consistent with results of other studies of the issue (McTiernan et
al, 1986; Cooper et al, 1989; Holm et al, 1989; Potter et al, 1995;
Yoo et al, 1997). This issue remains unresolved because of limited
statistical power in some of the earlier studies and a lack of infor-
mation on the joint ER and progesterone receptor (PR) status of the
patients in all but two of the studies (Potter et al, 1995; Yoo et al,
1997). A number of studies have demonstrated that the joint ER
and PR status may have greater prognostic value than either ER or
PR separately (McGuire, 1986; Ruder et al, 1989; Gamulin and
Romic-Stojkovic, 1991; Raabe et al, 1998).
Clarification of the association of alcohol with breast tumour
hormone receptor status may improve our understanding of the
role of alcohol in breast cancer aetiology. Using data from two
population-based case-control studies of breast cancer risk factors
in Los Angeles County, we examined the association of alcohol
and risk of breast cancer according to joint ER and PR status.
MATERIALS AND METHODS
Subjects
Subjects eligible to participate were English-speaking, white
(including Hispanic), female residents of Los Angeles County,
born in the USA, Canada, or Western Europe, with no history of
breast cancer. Eligible case subjects were all patients aged 40 years
or younger first diagnosed between 1 July 1983 and 1 January
1989, with histologically confirmed in situ or invasive breast
cancer and all patients aged 55—64 years first diagnosed between 1
March 1987 and 31 December 1989 with histologically confirmed
in situ or invasive breast cancer. Case subjects were identified
by the University of Southern California Cancer Surveillance
Program (CSP), the population-based cancer registry for Los
Angeles County. These study populations have been described in
detail elsewhere (Bernstein et al, 1994; Longnecker et al, 1995).
Briefly, a total of 744 (77%) of 969 eligible patients aged 40
years or younger completed the interview. Of the 225 eligible case
subjects who did not participate, the physician refused to allow
contact with 54 (6% of eligible patients), 27 (3%) could not be
interviewed because of mental or physical health problems or
because they had died, 111 (11%) refused to be interviewed, 12
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(1%) moved out of Los Angeles County and could not be inter-
viewed in person, and 21 (2%) were lost to follow-up.
One control subject was individually matched by birth date
(within 3 years), parity (nulliparous vs parous) and neighbourhood
to each of the 744 young breast cancer patients who completed the
interview. Control subjects were selected from housing units in a
pre-defined walk pattern in the neighbourhood where the case lived
at the time of her breast cancer diagnosis. The response rate among
eligible controls was 79% based on the total number of controls we
attempted to recruit in order to recruit 744 successfully.
A total of 1579 (67%) of 2373 eligible patients aged 55—64
years completed the interview. Physicians recommended against
our contacting 128 (5% of eligible subjects) patients, 419 (18%)
patients refused to be interviewed, 230 (10%) patients were too ill
or had died and we were unable to locate 17 (< 1%) patients.
One control subject was individually matched to 1506 of the
1579 interviewed breast cancer patients on birth date (within 3
years) and neighbourhood of residence. Control recruitment was
handled in the same manner as for the study of younger women.
We were unable to identify and interview an eligible control for
the remaining 73 case subjects. The response rate among eligible
control subjects was 80%.
Demographics
Detailed information regarding demographic characteristics and
reproductive histories as well as other known or suspected breast
cancer risk factors was obtained by face-to-face interview with
each subject. For each case and control pair (and for unmatched
case patients in the study of older women), a reference date was
created that was the date 12 months before the index patient￿s
breast cancer diagnosis. Information obtained by interview
includes only those exposures that occurred before the reference
date.
Alcohol consumption
The participants were queried about the number of drinks of beer,
wine and liquor that they consumed per week on average at ages
18, 25 and the reference age (women aged 40 years or younger)
and at ages 25, 40 and the reference age (women aged 55—64).
Results pertaining to alcohol consumption before the reference age
added little information and are not shown. We calculated the
average number of grams of alcohol consumed per day as the
number of drinks per day for each type of alcoholic beverage
multiplied by the estimated grams of alcohol in each beverage,
which we assumed to be 12.8 for one serving of beer, 10.9 for one
4 oz glass of wine and 15.0 for one mixed drink (USDA, 1986).
Exclusions
For the purposes of this study, we excluded 11 case patients and 16
control subjects from the study of younger women because the
women were no longer menstruating, and we excluded 13 case
patients and 14 control subjects who did not know their family
history of breast cancer because they had been adopted. A total of
720 case patients and 714 control subjects remained in the study of
pre-menopausal women. In addition, we excluded 419 case
patients (of the 1579 matched and unmatched case patients) and
415 control subjects from the study of older women for the
following reasons: premenopausal (still menstruating and not
using hormone-replacement therapy: 58 case patients and 51
control subjects), unknown age at menopause (usually hysterec-
tomy without bilateral oophorectomy: 352 case patients and 360
control subjects) or incomplete information on family history,
education, alcohol consumption, pregnancies, breastfeeding or
weight (nine case patients and four control subjects). A total of
1160 case patients and 1091 control subjects remained in the study
of post-menopausal women.
ER and PR status
CSP abstracts which include copies of the patients￿ pathology
reports were reviewed for ER and PR status (positive or negative)
for each breast cancer patient in the two studies. Medical and
pathology records were requested and reviewed at the hospital of
diagnosis if the information was not included in the CSP records
for the patient. In both studies, for over 50% of the women who
had missing receptor status data, the charts were located but results
of the receptor assays, if done, were not in the record. The chart
was unavailable, generally due to destruction or hospital closure,
for about one-third of the women with missing data. ER or PR
status, but not both, was available for about 10% of the women
with missing data.
Of the 720 premenopausal patients with complete interview
information, we retrieved ER status for 441 (61%), PR status for
425 (59%) and joint ER/PR status for 424 (59%). A total of ten
patients had ER-positive tumours and seven had ER-negative
tumours but were missing PR status and one patient had a PR-
positive tumour but was missing ER status. We have included 405
case patients in the statistical analyses whose tumours were known
to be ER-positive/PR-positive, ER-positive/PR-negative or ER-
negative/PR-negative [there were too few women with ER-nega-
tive/PR-positive tumours (n = 19) to permit useful analyses], 296
women with unknown tumour ER or PR status and 714 control
subjects.
We retrieved ER status for 805 (69%), PR status for 760 (66%)
and joint ER/PR status for 760 (66%) of the 1160 postmenopausal
patients with complete interview information included in the study
of women 55—64 years of age. A total of 34 women had ER-posi-
tive tumours and 11 had ER-negative tumours but were missing
PR status, and no women had PR status but were missing ER
status. We included 736 case patients whose tumours were known
to be ER-positive/PR-positive, ER-positive/PR-negative, or ER-
negative/PR-negative [there were too few women with ER-nega-
tive/PR-positive tumours (n = 24) to permit useful analysis], 400
Table 1 Joint distribution of ER and PR status among breast cancer
patients with known tumour hormone receptor status
Premenopausal Postmenopausal
Joint ER/PR status Frequency % Frequency %
(n = 424) (n = 760)
ER+/PR+ 205 (49) 450 (59)
ER+/PR– 52 (12) 159 (21)
ER–/PR+ 18 (4) 24 (3)
ER–/PR– 149 (35) 127 (17)
Positive = +; negative = –.1310 SM Enger et al
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women with unknown tumour ER or PR status, and 1091 control
subjects in the statistical analyses.
Statistical analyses
We compared the risk factor distributions for patients with known
ER and PR status to those of patients whose ER and PR status was
unknown using the c2 test. ORs and 95% CIs were calculated to
estimate the breast cancer risk associated with alcohol consump-
tion using unconditional logistic regression methods within joint
ER and PR status subgroups using four separate models as
follows: ER-positive/PR-positive vs controls, ER-positive/PR-
negative vs controls, ER-negative/PR-negative vs controls, and
ER unknown/PR unknown vs controls. Pair matching was not
retained in the analyses in order to maximize the number of
subjects to be included in the analyses. The results were not mate-
rially different when the matching was retained. We used the two-
sided P-value associated with the coefficient fit to the median
value of each category of the variable to test for trend in effect
across categories of a risk factor. We used polytomous logistic
regression analysis to test for heterogeneity in the effect of alcohol
consumption as a continuous variable across response functions of
each of the hormone receptor status subgroups, with the control
subjects serving as the reference group. SAS statistical software
was used to perform all statistical analyses (SAS Institute, Cary,
NC, USA).
We included the matching variables [age at reference year
(continuous variable) and socio-economic status (five categories
based on census tract of residence)] as covariates in the multi-
variate models for both studies. For premenopausal women, we
Table 2 Distribution of patient and tumour factors among patients with known and missing tumour hormone receptors status
Premenopausal Postmenopausal
ER and PR ER or PR ER and PR ER or PR
known missing known missing
Factor n % n % Pn % n % P
Age at diagnosis (years)
21–25 8 2.0 7 2.3
26–30 30 7.4 20 6.6
31–35 134 33.0 82 27.2
36–40 234 57.6 193 63.9 0.25
55–59 313 42.5 177 44.3
60–64 423 57.5 223 55.8 0.57
Stage
In situ 16 3.9 50 16.6 17 2.3 91 22.7
Localized 195 48.0 137 45.4 440 59.8 226 56.5
Regional 173 42.6 98 32.4 262 35.6 74 18.5
Metastatic 11 2.7 9 3.0 16 2.2 5 1.3
Unstageable 11 2.7 8 2.6 0.001 1 0.1 4 1.0 0.001
Age at menarche (years)
< 12 105 25.9 91 30.1 145 19.7 85 21.3
12 119 29.3 85 28.1 191 26.0 108 27.0
13 116 28.6 87 28.8 230 31.3 107 26.8
³ 14 66 16.3 39 12.9 0.45 170 23.1 100 25.0 0.39
Age at first full-term pregnancy (years)
Never pregnant 152 37.4 116 38.4 120 16.3 61 15.3
< 20 55 13.5 43 14.2 95 12.9 48 12.0
20–24 95 23.4 58 19.2 287 39.0 152 38.0
25–29 69 17.0 56 18.5 151 20.5 93 23.3
³ 30 35 8.6 29 9.6 0.74 83 11.3 46 11.5 0.87
Number of full-term pregnancies
0 152 37.4 116 38.4 120 16.3 61 15.3
1 74 18.2 61 20.2 104 14.1 45 11.3
2 123 30.3 79 26.2 208 28.3 117 29.3
3 38 9.4 30 9.9 156 21.2 103 25.8
³ 4 19 4.7 16 5.3 0.71 148 20.1 74 18.5 0.31
Age at menopause
< 45 124 16.8 52 13.0
45–49 187 25.4 111 27.8
50–54 344 46.7 184 46.0
³ 55 81 11.0 53 13.3 0.20
Family history
No 357 87.9 237 78.5 612 83.2 315 78.8
Yes 44 10.8 57 18.9 124 16.8 85 21.3
Unknown 5 1.2 8 2.6 0.002 0.07Alcohol and breast cancer hormone receptors 1311
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also included as categorical variables the following factors: age at
menarche (< 12, 12, 13, ‡ 14 years), age at first full-term preg-
nancy (never, < 20, 20—24, 25—29, ‡ 30 years), number of full-term
pregnancies (0, 1, 2, 3, ‡ 4), lifetime months of breastfeeding (0,
1—6, 7—15, ‡ 16), years of use of oral contraceptives (0, 1—4, 5—9,
‡ 10), average hours per week of physical activity after menarche
(0, 0.1—0.7, 0.8—1.6, 1.7—3.7, ‡ 3.8) and first-degree family history
of breast cancer (yes/no).
For postmenopausal women, we included as categorical vari-
ables in all multivariate models age at menarche (< 12, 12, 13,
‡ 14 years), age at first full-term pregnancy (never, < 20, 20—24,
25—29, ‡ 30 years), number of full-term pregnancies (0, 1, 2, 3,
‡ 4), lifetime months of breastfeeding (0, 1—3, 4—6, 7—15, ‡ 16),
age at menopause (< 45, 45—49, 50—54, ‡ 55 years), use of
oestrogen-only hormone-replacement therapy (0, 1—12, 13—72,
73—120, ‡ 121 months), use of combined oestrogen and progestin
hormone-replacement therapy (0, 1—12, 13—72, 73—120, ‡ 121
months), body-mass index (BMI) at the reference date (< 21.8,
21.8—23.9, 24.0—27.3, ‡ 27.4 kg/m2), physical activity (a combi-
nation variable based on average MET-hours (the ratio of the
metabolic rate associated with a given activity to the resting meta-
bolic rate) per week (MH) of activity before/after age 40: 0/0,
low/low (at least one is > 0), low/high, high/low, high/high, where
low is < 17.6, and high is ‡ 17.6 MH), education (less than high
school, high school, partial college, college or graduate/profes-
sional training) and first-degree family history of breast cancer
(yes/no).
RESULTS
As expected, a greater proportion of post-menopausal than pre-
menopausal patients had tumours that expressed both ER and PR,
while twice the proportion of pre-menopausal compared with post-
menopausal patients had tumours that expressed neither ER nor
PR (Table 1). Tumours that expressed PR but not ER were rare in
both groups.
In general, the distributions of various patient factors were
not different between the group of patients for whom receptor status
was ascertained and the group with missing receptor status informa-
tion (Table 2). However, we observed that a greater proportion of
patients with unknown than with known hormone-receptor status had
in situ tumours, probably due to insufficient tissue for the receptor
assays. Among premenopausal patients with unknown receptor
status, the proportion with in situ disease was fourfold greater than in
those with disease of known receptor status. Among postmenopausal
breast cancer patients, the proportion of in situ cases with unknown
receptor status was nearly tenfold greater. We also observed that a
greater proportion of premenopausal and postmenopausal patients
with missing receptor status had a first-degree family history of
breast cancer than did patients whose receptor status was ascertained.
Among premenopausal women with known receptor status,
alcohol consumption was generally unrelated to risk of breast
cancer regardless of receptor type (Table 3). Because the pre-
menopausal women consumed fairly low levels of alcohol, the
highest category of consumption in these analyses was 14 g of
alcohol per day or more (approximately one drink). An association
of alcohol consumption with risk of breast cancer was observed,
however, among cases with unknown receptor status.
Among post-menopausal women, alcohol consumption was
associated more with increased risk of ER-positive/PR-positive
breast cancer than with tumours of other receptor type (Table 3).
Women who consumed at least 27 g/day on average (approxi-
mately two drinks) in the recent past experienced more than a 75%
increase in risk of ER-positive/PR-positive breast cancer. We
obtained similar findings for alcohol consumption at age 40 and
for maximum alcohol consumption (the maximum of ages 25, 40
and the reference age) (results not shown). The results were not
materially different when analysed for invasive tumours only (not
shown). The alcohol coefficients compared across receptor status
subgroups showed no statistically significant differences in poly-
tomous logistic regression analyses with alcohol consumption
modelled as a continuous variable.
Table 3 Association of alcohol consumption with breast cancer risk, according to joint oestrogen receptor (ER) and progesterone receptor (PR) statusa
ER+/PR+ ER+/PR– ER–/PR– ER unknown/PR unknown
Alcohol (g/day) Controls Cases ORb (95% CI) Cases ORb (95% CI) Cases ORb (95% CI) Cases ORb (95% CI)
Premenopausal
0 385 110 1.00 37 1.00 85 1.00 157 1.00
1–5 135 30 0.73 (0.46–1.15) 6 0.45 (0.18–1.10) 20 0.68 (0.40–1.16) 51 0.97 (0.66–1.43)
6–13 118 37 1.07 (0.69–1.65) 2 0.16 (0.04–0.69) 23 0.90 (0.53–1.51) 48 1.01 (0.68–1.52)
14+ 88 28 1.10 (0.67–1.80) 7 0.71 (0.30–1.68) 21 1.04 (0.60–1.81) 46 1.27 (0.83–1.94)
Trend P 0.56 0.21 0.84 0.29
OR per 13 g 1.10 (0.91–1.32) 0.88 (0.59–1.30) 1.08 (0.89–1.31) 1.18 (1.03–1.37)
Postmenopausal
0 590 239 1.00 90 1.00 71 1.00 236 1.00
1–13 329 122 0.97 (0.74–1.27) 38 0.75 (0.49–1.14) 33 0.81 (0.52–1.26) 95 0.75 (0.56–1.00)
14–26 109 46 1.18 (0.80–1.75) 21 1.36 (0.80–2.33) 12 0.91 (0.47–1.75) 34 0.84 (0.54–1.29)
27+ 63 43 1.76 (1.14–2.71) 10 1.10 (0.53–2.26) 11 1.37 (0.68–2.76) 35 1.43 (0.90–2.27)
Trend P 0.03 0.65 0.77 0.79
OR per 13 g 1.13 (1.01–1.25) 1.05 (0.90–1.24) 0.96 (0.79–1.18) 1.06 (0.95–1.18)
aThere were too few women with ER–/PR+ tumours to permit useful analysis (see methods). bOdds ratios adjusted for age at reference year, socioeconomic
status, education, age at menarche, age at first full-term pregnancy, parity, lifetime months of breastfeeding, physical activity and family history. In the analysis
that included pre-menopausal women, years of use of oral contraceptives was also included in the multivariate models. In the analysis that included
postmenopausal women, age at menopause, oestrogen-only replacement therapy, combined oestrogen and progestin-replacement therapy and BMI were also
included in the multivariate models (see Methods).1312 SM Enger et al
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We evaluated potential interactions of alcohol consumption with
BMI and with ostrogen-replacement therapy (ERT) use for ER-
positive/PR-positive tumours among postmenopausal women,
because these breast cancer risk factors also represent oestrogen
exposures (Table 4). We found that risk of ER-positive/PR-posi-
tive breast cancer was increased among the heaviest women
(women in the ￿high￿ BMI category) regardless of alcohol
consumption level. We observed a 2.5-fold increase in ER-posi-
tive/PR-positive risk of breast cancer among heavier women who
consumed at least 14 g of alcohol per day on average in the
recent past compared to thinner women who did not consume
alcohol. Among thinner women, consumption of 14 g of alcohol
per day was associated with about a 50% increase in risk of
ER-positive/PR-positive tumours compared to non-drinkers.
Because the increase in risk of breast cancer across levels of
alcohol intake was similar for the low and high BMI groups,
evidence of effect modification by BMI for ER-positive/PR-posi-
tive breast cancer was not compelling. In a similar analysis, we
observed no evidence of effect modification by ERT use of the
association of alcohol consumption with ER-positive/PR-positive
breast cancer.
DISCUSSION
We observed an increased risk of ER-positive/PR-positive breast
cancer among postmenopausal women who reported consumption
of high levels of alcohol (> 27 g/day). Alcohol consumption was
not associated with other hormone receptor subtypes post-
menopausally and was generally not related to risk of any specific
subtype among premenopausal patients. These results are
generally consistent with those from a large case-control study
conducted in New York, USA (Nasca et al, 1994), which included
more than 1100 premenopausal and postmenopausal patients with
breast cancer. In that study, Nasca and colleagues reported an
increased risk of ER-positive, but not ER-negative, breast cancer
at the highest levels of alcohol consumption. However, pre-
menopausal and postmenopausal patients were combined and
results for PR status were not presented. Five other studies have
examined alcohol consumption in relation to risk of breast cancer
by tumour hormone receptor status with highly mixed results: two
reported no association of alcohol with tumour ER status (Cooper
et al, 1989) or with joint ER/PR status (Yoo et al, 1997), one
reported positive associations of alcohol with ER-positive and ER-
negative tumours (McTiernan et al, 1986), one reported a modest
increase in risk of ER-negative breast cancer with alcohol
consumption (Holm et al, 1989), and one reported a positive asso-
ciation of alcohol consumption with risk of ER-negative/PR-nega-
tive breast cancer (Potter et al, 1995). All of the previous studies
except one (Potter et al, 1995) presented the alcohol—receptor
status results for both premenopausal and postmenopausal women
combined. Previously reported findings that suggested an interac-
tion between alcohol and BMI, and between alcohol and ERT use,
within receptor status subgroups (Gapstur et al, 1995) were not
replicated in our study.
Substantial epidemiological evidence supports an association
of even modest alcohol consumption (one drink per day) with
increased risk of breast cancer (Longnecker, 1994). In addition,
results from experimental and cross-sectional data suggest that
acute and chronic alcohol consumption increase endogenous
oestrogen levels of both premenopausal and postmenopausal
women (Mendelson et al, 1981, 1987, 1988, 1989; Teoh et al,
Table 4 Interactions of alcohol consumption with body-mass index (BMI) and with oestrogen-replacement therapy (ERT) use in relation
to ER+/PR+ breast cancer risk (postmenopausal women)
Alcohol
intake ER+/PR+
(g/d) Cases Controls OR (95% CI)
BMIa
Low
0 71 258 1.00
1–13 58 178 1.15 (0.77–1.72)
14+ 42 103 1.49 (0.95–2.34)
High
0 168 332 1.96 (1.41–2.74)
1–13 64 151 1.61 (1.08–2.41)
14+ 47 69 2.53 (1.59–4.04)
P for interactionb 0.52
ERT usec
Never
0 121 319 1.00
1–13 59 168 1.05 (0.72–1.54)
14+ 45 83 1.52 (0.98–2.34)
Ever
0 118 271 1.30 (0.95–1.78)
1–13 63 161 1.17 (0.80–1.78)
14+ 44 89 1.66 (1.07–2.58)
P for interactionb 0.47
aCutpoint for low vs high BMI: 23.7. bInteraction P-values determined from likelihood ratio test with 1° of freedom. cOestrogen-replacement
therapy use includes use of oestrogen-only-replacement therapy and combined oestrogen and progestin-replacement therapy.Alcohol and breast cancer hormone receptors 1313
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1988; Katsouyanni et al, 1991; Gavaler et al, 1993; Reichman et
al, 1993; Dorgan et al, 1994; Hankinson et al, 1995). Overall, this
evidence combined with results of a prospective study of endoge-
nous oestrogens and postmenopausal breast cancer (Toniolo et al,
1995) indicate that the effect of alcohol on breast cancer risk may
be mediated by oestrogen. However, analysis of data from the
same prospective study revealed no clear associations between
endogenous oestrogen levels and breast tumour hormone receptor
status (Zeleniuch-Jacquotte et al, 1995), raising questions about
the mechanisms underlying the association of alcohol consump-
tion and ER-positive/PR-positive breast tumours.
Studies such as the one presented here may help clarify whether
hormone receptor-positive and hormone receptor-negative breast
tumours represent different stages in the progression of the disease
or two distinct diseases with distinct aetiologies. The scientific
literature includes evidence that can be interpreted to support
either of these theories (Mobbs et al, 1987; Tani et al, 1988; Habel
and Stanford, 1993; Zeleniuch-Jacquotte et al, 1995). Our finding
that alcohol is more strongly associated with ER-positive/PR-posi-
tive risk of breast cancer among postmenopausal women supports
the theory that hormone receptor status defines distinct diseases
rather than different stages of the same disease.
This was the largest study to date to evaluate the association
between alcohol consumption and risk of breast cancer by ER or
PR type. Although generalization of findings from this study may
be limited by the somewhat low ER and PR status recovery rates,
it seems unlikely that the reasons for missing receptor status would
have been related to receptor subtype or alcohol consumption
patterns of the patients, especially since the majority of missing
data was due to hospital policy (i.e. the destruction of charts inac-
tive for over 7 years). Also, the distributions of most other breast
cancer risk factors were generally similar for patients with known
and unknown ER and PR status, and were therefore unlikely to
introduce serious bias in the estimates derived from multivariate
analyses. Another concern is that the hormone receptor status
assays were performed in several different laboratories. However,
results of two large European collaborative studies of steroid
receptor distribution demonstrated that receptor assays were
remarkably consistent across laboratories (Romain et al, 1995,
1996). In addition, the ER/PR distributions for both pre-
menopausal and postmenopausal women in the present study are
consistent with distributions reported from other studies (Bland et
al, 1981; Thorpe, 1988; Potter et al, 1995).
In summary, these data suggest that alcohol may preferentially
increase risk of ER-positive/PR-positive breast cancer in post-
menopausal women, and that the association is not modified by
BMI or ERT use. Although these findings support the hypothesis
of an oestrogen-mediated effect of alcohol consumption on risk of
breast cancer, further research is needed to determine whether the
effects of alcohol consumption are mediated through interaction
with steroid hormone receptors or through some other, possibly
non-oestrogenic, pathway.
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